Skip to main content
. 2022 Mar 1;13:848327. doi: 10.3389/fimmu.2022.848327

Figure 2.

Figure 2

CRISPR/Cas9 directly edits PD-1/PD-L1 to regulate tumor immunity. CRISPR/Cas9 technology can edit the PD-1 gene in primary T cells, CTLs, NK cells and B cells through different delivery methods to enhance antitumor immunity through different mechanisms. CRISPR/Cas9 knockdown of PD-L1 in tumor cells promotes tumor antigen presentation, immune cell proliferation and cytotoxicity in the tumor microenvironment, and improves tumor chemotherapy resistance.